Reuters logo
BRIEF- Basilea Pharmaceutica announces isavuconazole received QIDP designation from FDA
July 17, 2014 / 7:41 AM / 3 years ago

BRIEF- Basilea Pharmaceutica announces isavuconazole received QIDP designation from FDA

July 16(Reuters) - Basilea Pharmaceutica AG :

* Says U.S. Food and Drug Administration designated

Isavuconazole as Qualified Infectious Disease Product (QIDP) for oral and intravenous treatment of invasive candidiasis Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below